An Italian biotech company, Aptadir Therapeutic Srl, which is developing a new class of RNA therapies, launched on 24 September with pre-seed funding of $1.6 million and plans to tackle cancer by blocking aberrant DNA methylation. DNA methylation is an essential biological process that enables the expression of genes in humans. But this process can be thrown off balance by external factors such as age or diets, leading to cancer and genetic disorders.
